RiaSTAP™ Fibrinogen Concentrate(Human)
Manufacturer: CSL Behring
General Information: RiaSTAP is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
|
| |
| Products |
Size |
NDC |
PI |
MSDS |
| RiaSTAP |
1100mg/vial |
63833-0891-51 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to RiaSTAP, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and/or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |